de LPL Financial Invesco Biotechnology & Genome ETF PBE Historial de posiciones en acciones
Compró
Mantenido
Vendió
| Trimestre | Valor de mercado | Estado | Núm. de acciones |
Cambio en la participación | Valor operado | Peso en el portafolio | Posición de la cartera | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | USD 9.44 M | Comprar |
97,039
+4,717
| +5% | +USD 443 k | ﹤0.01% | 2249 |
|
|
2026
Q2 | USD 8.28 M | Comprar |
92,322
+5,582
| +6% | +USD 460 k | ﹤0.01% | 2320 |
|
|
2026
Q1 | USD 6.87 M | Vender |
86,740
-10,564
| -11% | -USD 854 k | ﹤0.01% | 2352 |
|
|
2025
Q4 | USD 7.99 M | Comprar |
97,304
+4,617
| +5% | +USD 357 k | ﹤0.01% | 2120 |
|
|
2025
Q3 | USD 6.48 M | Comprar |
92,687
+15,792
| +21% | +USD 1.07 M | ﹤0.01% | 2247 |
|
|
2025
Q2 | USD 4.93 M | Vender |
76,895
-5,869
| -7% | -USD 364 k | ﹤0.01% | 2322 |
|
|
2025
Q1 | USD 5.25 M | Vender |
82,764
-9,341
| -10% | -USD 629 k | ﹤0.01% | 2110 |
|
|
2024
Q4 | USD 6.13 M | Comprar |
92,105
+1,503
| +2% | +USD 104 k | ﹤0.01% | 1906 |
|
|
2024
Q3 | USD 6.33 M | Vender |
90,602
-10,157
| -10% | -USD 703 k | ﹤0.01% | 1797 |
|
|
2024
Q2 | USD 6.53 M | Comprar |
100,759
+3,693
| +4% | +USD 234 k | ﹤0.01% | 1656 |
|
|
2024
Q1 | USD 6.28 M | Comprar |
97,066
+14,003
| +17% | +USD 911 k | ﹤0.01% | 1624 |
|
|
2023
Q4 | USD 5.47 M | Comprar |
83,063
+32,972
| +66% | +USD 1.92 M | ﹤0.01% | 1632 |
|
|
2023
Q3 | USD 2.86 M | Vender |
50,091
-2,936
| -6% | -USD 179 k | ﹤0.01% | 2003 |
|
|
2023
Q2 | USD 3.25 M | Vender |
53,027
-5,691
| -10% | -USD 355 k | ﹤0.01% | 1855 |
|
|
2023
Q1 | USD 3.69 M | Comprar |
58,718
+14,840
| +34% | +USD 956 k | ﹤0.01% | 1700 |
|
|
2022
Q4 | USD 2.79 M | Comprar |
43,878
+1,261
| +3% | +USD 80 k | ﹤0.01% | 1825 |
|
|
2022
Q3 | USD 2.51 M | Comprar |
42,617
+13,399
| +46% | +USD 826 k | ﹤0.01% | 1811 |
|
|
2022
Q2 | USD 1.69 M | Vender |
29,218
-3,435
| -11% | -USD 198 k | ﹤0.01% | 2159 |
|
|
2022
Q1 | USD 2.02 M | Vender |
32,653
-8,543
| -21% | -USD 521 k | ﹤0.01% | 2053 |
|
|
2021
Q4 | USD 2.93 M | Comprar |
41,196
+677
| +2% | +USD 49 k | ﹤0.01% | 1811 |
|
|
2021
Q3 | USD 3.03 M | Comprar |
40,519
+2,136
| +6% | +USD 163 k | ﹤0.01% | 1736 |
|
|
2021
Q2 | USD 2.97 M | Comprar |
38,383
+3,360
| +10% | +USD 250 k | ﹤0.01% | 1691 |
|
|
2021
Q1 | USD 2.58 M | Vender |
35,023
-270
| -0.8% | -USD 20.4 k | ﹤0.01% | 1654 |
|
|
2020
Q4 | USD 2.48 M | Comprar |
35,293
+1,712
| +5% | +USD 108 k | ﹤0.01% | 1533 |
|
|
2020
Q3 | USD 1.9 M | Comprar |
33,581
+9,653
| +40% | +USD 567 k | ﹤0.01% | 1493 |
|
|
2020
Q2 | USD 1.39 M | Comprar |
23,928
+1,299
| +6% | +USD 70.8 k | ﹤0.01% | 1587 |
|
|
2020
Q1 | USD 1.05 M | Comprar |
22,629
+1,356
| +6% | +USD 70.7 k | ﹤0.01% | 1582 |
|
|
2019
Q4 | USD 1.19 M | Vender |
21,273
-1,508
| -7% | -USD 78.6 k | ﹤0.01% | 1707 |
|
|
2019
Q3 | USD 1.08 M | Vender |
22,781
-5,678
| -20% | -USD 291 k | ﹤0.01% | 1679 |
|
|
2019
Q2 | USD 1.52 M | Vender |
28,459
-8,916
| -24% | -USD 463 k | ﹤0.01% | 1418 |
|
|
2019
Q1 | USD 2.06 M | Vender |
37,375
-157
| -0.4% | -USD 8.3 k | ﹤0.01% | 1178 |
|
|
2018
Q4 | USD 1.77 M | Vender |
37,532
-1,655
| -4% | -USD 85.1 k | ﹤0.01% | 1139 |
|
|
2018
Q3 | USD 2.33 M | Vender |
39,187
-286
| -0.7% | -USD 16.7 k | 0.01% | 1081 |
|
|
2018
Q2 | USD 2.16 M | Comprar |
39,473
+578
| +1% | +USD 29.4 k | 0.01% | 1089 |
|
|
2018
Q1 | USD 1.91 M | Vender |
38,895
-3,164
| -8% | -USD 161 k | 0.01% | 1139 |
|
|
2017
Q4 | USD 1.98 M | Comprar |
42,059
+34
| +0.1% | +USD 1.59 k | 0.01% | 1058 |
|
|
2017
Q3 | USD 2.1 M | Comprar |
42,025
+58
| +0.1% | +USD 2.75 k | 0.01% | 965 |
|
|
2017
Q2 | USD 1.92 M | Vender |
41,967
-9,420
| -18% | -USD 407 k | 0.01% | 961 |
|
|
2017
Q1 | USD 2.15 M | Vender |
51,387
-1,888
| -4% | -USD 79.1 k | 0.01% | 796 |
|
|
2016
Q4 | USD 2.1 M | Vender |
53,275
-5,856
| -10% | -USD 236 k | 0.02% | 772 |
|
|
2016
Q3 | USD 2.48 M | Vender |
59,131
-2,758
| -4% | -USD 113 k | 0.02% | 659 |
|
|
2016
Q2 | USD 2.38 M | Vender |
61,889
-82,434
| -57% | -USD 3.23 M | 0.02% | 676 |
|
|
2016
Q1 | USD 5.72 M | Vender |
144,323
-35,053
| -20% | -USD 1.36 M | 0.02% | 654 |
|
|
2015
Q4 | USD 8.68 M | Comprar |
179,376
+88,740
| +98% | +USD 4.38 M | 0.02% | 492 |
|
|
2015
Q3 | USD 4.36 M | Vender |
90,636
-7,448
| -8% | -USD 416 k | 0.02% | 513 |
|
|
2015
Q2 | USD 5.72 M | Comprar |
98,084
+11,707
| +14% | +USD 669 k | 0.03% | 463 |
|
|
2015
Q1 | USD 4.79 M | Comprar |
86,377
+11,794
| +16% | +USD 638 k | 0.02% | 534 |
|
|
2014
Q4 | USD 3.74 M | Comprar |
74,583
+12,090
| +19% | +USD 592 k | 0.02% | 606 |
|
|
2014
Q3 | USD 2.87 M | Comprar |
62,493
+718
| +1% | +USD 32.3 k | 0.02% | 687 |
|
|
2014
Q2 | USD 2.7 M | Vender |
61,775
-29,222
| -32% | -USD 1.18 M | 0.02% | 724 |
|
|
2014
Q1 | USD 3.79 M | Comprar |
90,997
+6,207
| +7% | +USD 266 k | 0.02% | 541 |
|
|
2013
Q4 | USD 3.14 M | Comprar |
84,790
+13,699
| +19% | +USD 491 k | 0.02% | 614 |
|
|
2013
Q3 | USD 2.45 M | Comprar |
71,091
+27,470
| +63% | +USD 910 k | 0.02% | 680 |
|
|
2013
Q2 | USD 1.26 M | Comprar |
+43,621
| Nuevas | +USD 1.24 M | 0.01% | 972 |
|
Otros fondos que tienen PBE en su cartera
Posición de LPL Financial en PBE: resumen de T3 2026
LPL Financial aumentó su participación en Invesco Biotechnology & Genome ETF (PBE) en 5.1% durante T3 2026, al comprar aproximadamente USD 443 k y elevar la posición a 97,039 acciones con un valor de USD 9.44 M. La posición representa ﹤0.01% de la cartera y ocupa el puesto #2249.
LPL Financial reportó por primera vez una posición en PBE en T2 2013 y la ha mantenido durante 54 trimestres desde entonces. Al cierre de T3 2026, 55 fondos que sigue Wall St. Rank mantienen una posición en PBE.
- Al cierre de T3 2026, LPL Financial tenía 97,039 acciones de Invesco Biotechnology & Genome ETF con un valor de USD 9.44 M.
- LPL Financial compró 4,717 acciones de Invesco Biotechnology & Genome ETF en T3 2026, por un monto estimado de USD 443 k.
- Invesco Biotechnology & Genome ETF representó ﹤0.01% de la cartera de LPL Financial en T3 2026 y fue su posición número 2249.
- LPL Financial reportó por primera vez una posición en Invesco Biotechnology & Genome ETF en T2 2013 y la ha mantenido durante 54 trimestres desde entonces.
- Al cierre de T3 2026, 55 fondos que sigue Wall St. Rank tenían Invesco Biotechnology & Genome ETF en cartera.
Según el Informe 13F de LPL Financial correspondiente a T3 2026, presentado el 6 nov 2026.